Report #2851444

Received Jul 28, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: Jun 1, 2025
Onset: Jun 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	946065	IM

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Our Patient Received Twinrix As A Second Dose After Receiving A First Dose of Heplisav-B; Initial report received on 15-Jul-2025. A pharmacist reported that a 31-year-old male patient (race and ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and then received TWINRIX as a second dose. No medical history or concomitant medications were reported. In Jun-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 946065, expiration date 02-Nov-2027, NDC # 43528-0003-05, route and site not available). On an unknown date, after having been vaccinated with HEPLISAV-B, the patient received a dose of TWINRIX (no details provided) as a second dose of hepatitis B vaccination. The reporter stated that the patient had no other side effects reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.